<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787498</url>
  </required_header>
  <id_info>
    <org_study_id>PLX124-02</org_study_id>
    <nct_id>NCT03787498</nct_id>
  </id_info>
  <brief_title>A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics&#xD;
      and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or&#xD;
      Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>First dose of study drug through at least 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak concentration (Tmax) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (t1/2) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (Kel)</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience dose limiting toxicity as defined in the protocol</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Dose escalation will be guided by a modified continuous reassessment method (mCRM) using a Bayesian logistic regression model that follows the escalation with overdose control (EWOC) principle. In this method, a decision to escalate to the next dose level is based on a review of all subjects who have completed the DLT observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall complete remission (OCR) rate</measure>
    <time_frame>From the first dose of study drug until the date of documented best response to treatment, assessed up to 18 months</time_frame>
    <description>AML - Complete Remission (CR) + CR with incomplete hematological recovery (CRi); MDS - CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From the first dose of study drug until the date of documented response to treatment, assessed up to 18 months</time_frame>
    <description>AML - Complete Remission (CR) + CR with incomplete hematologic recovery (CRi) + Partial Remission (PR); MDS - CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>EFS time is defined as the time from the first dose of PLX2853 to treatment failure, relapse after initial response or death from any cause, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the first dose of study drug until the date of death from any cause, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Relapsed Acute Myeloid Leukemia (AML)</condition>
  <condition>Refractory Acute Myeloid Leukemia (AML)</condition>
  <condition>High-risk Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>PLX2853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX2853</intervention_name>
    <description>Tablets</description>
    <arm_group_label>PLX2853</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of one of the following myeloid malignancies, based on the 2016&#xD;
             revision of the World Health Organization classification:&#xD;
&#xD;
             A. Relapsed or refractory AML.&#xD;
&#xD;
             I. Subjects must have received no more than 3 prior induction therapies and have no&#xD;
             standard therapeutic option that is expected to result in a clinical benefit.&#xD;
&#xD;
             B. Relapsed or refractory MDS.&#xD;
&#xD;
             I. Subjects must have high-risk disease (intermediate or greater disease according to&#xD;
             the revised International Prognostic Scoring System [IPSS-R]).&#xD;
&#xD;
             II. Subjects must have received no more than 3 prior therapies, 1 of which must have&#xD;
             included a hypomethylating agent such as azacytidine or decitabine.&#xD;
&#xD;
             III. Subjects must have no standard therapeutic option that is expected to result in a&#xD;
             clinical benefit.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.&#xD;
&#xD;
          4. Life expectancy of ≥3 months in the judgment of the investigator.&#xD;
&#xD;
          5. Adequate renal, hepatic, and coagulation parameters:&#xD;
&#xD;
             A. Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) ≥60&#xD;
             mL/min.&#xD;
&#xD;
             B. Total bilirubin ≤1.5 × ULN unless due to Gilbert's syndrome.&#xD;
&#xD;
             C. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.&#xD;
&#xD;
             D. Prothrombin time or international normalized ratio ≤1.5 × ULN.&#xD;
&#xD;
             E. Activated partial thromboplastin time ≤1.5 × ULN.&#xD;
&#xD;
          6. Women of child-bearing potential must have a negative pregnancy test at Screening and&#xD;
             must agree to use an effective form of contraception from the time of the negative&#xD;
             pregnancy test to 90 days after the last dose of study drug. Effective forms of&#xD;
             contraception include abstinence, hormonal contraception in conjunction with a barrier&#xD;
             method, or a double barrier method. Women of non-child-bearing potential may be&#xD;
             included if they are either surgically sterile or have been postmenopausal for ≥ 1&#xD;
             year.&#xD;
&#xD;
          7. Fertile men must agree to use an effective method of birth control during the study&#xD;
             and for 90 days after the last dose of study drug.&#xD;
&#xD;
          8. Resolution (to ≤Grade 1 or baseline) of all significant toxicity associated with prior&#xD;
             cancer therapy prior to study drug initiation. (Grade 2 alopecia or residual Grade 2&#xD;
             peripheral neuropathy is allowed.)&#xD;
&#xD;
          9. Willingness and ability to provide written informed consent prior to any study-related&#xD;
             procedures and to comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with a bromodomain inhibitor.&#xD;
&#xD;
          2. Any one of the following therapies:&#xD;
&#xD;
             A. Stem cell transplantation within 90 days of study drug initiation;&#xD;
&#xD;
             B. Active immunosuppressive therapy for graft-versus-host disease (GVHD);&#xD;
&#xD;
             C. GVHD prophylaxis within 2 weeks of study drug initiation.&#xD;
&#xD;
          3. Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.&#xD;
&#xD;
          4. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.&#xD;
&#xD;
          5. Active symptomatic central nervous system involvement of AML. (Individuals who have&#xD;
             had leptomeningeal disease that was effectively treated are eligible.)&#xD;
&#xD;
          6. A diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia in blast&#xD;
             crisis.&#xD;
&#xD;
          7. Known or suspected allergy to the study drug or any agent given in association with&#xD;
             this trial.&#xD;
&#xD;
          8. Women who are either pregnant or breast feeding.&#xD;
&#xD;
          9. Clinically significant cardiac disease.&#xD;
&#xD;
         10. Inability to take oral medication or significant nausea and vomiting, malabsorption,&#xD;
             or significant small bowel resection that, in the opinion of the Investigator, would&#xD;
             preclude adequate absorption.&#xD;
&#xD;
         11. Individuals who are known to be infected with HIV, hepatitis B virus (HBV), or&#xD;
             hepatitis C virus (HCV) or are known carriers of HBV or HCV. Individuals who are&#xD;
             positive for HCV antibody must be negative for HCV RNA by polymerase chain reaction&#xD;
             (PCR) to be eligible. Individuals with occult or prior HBV infection (defined as being&#xD;
             seropositive for total hepatitis B core antibody and seronegative for hepatitis B&#xD;
             surface antigen) may be included if HBV DNA is undetectable. These individuals must be&#xD;
             willing to undergo additional testing per local standard of care.&#xD;
&#xD;
         12. Active second malignancy with the exception of any of the following:&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or&#xD;
                  in situ cervical cancer;&#xD;
&#xD;
               -  Adequately treated Stage I cancer from which the subject is currently in&#xD;
                  remission and has been in remission for ≥2 years;&#xD;
&#xD;
               -  Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10&#xD;
                  ng/mL;&#xD;
&#xD;
               -  Any other cancer from which the patient has been disease-free for ≥3 years.&#xD;
&#xD;
         13. Major surgery or significant injury within the 14-day period prior to study drug&#xD;
             initiation.&#xD;
&#xD;
         14. Anti-cancer therapy in the period immediately preceding study drug initiation.&#xD;
&#xD;
         15. Any other medical, psychological, familial, sociologic, or geographic condition that,&#xD;
             in the judgement of the investigator, would potentially hamper compliance with the&#xD;
             study protocol or interfere with the study endpoints or the subject's ability to&#xD;
             participate in the study.&#xD;
&#xD;
         16. Participation in any other therapeutic clinical study. (Participation in observational&#xD;
             or registry trials is allowed.)&#xD;
&#xD;
         17. Individuals who are on active anticoagulation therapy (e.g., warfarin, factor Xa&#xD;
             inhibitors, thrombin inhibitors, heparin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>27287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian / Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 23, 2018</study_first_submitted>
  <study_first_submitted_qc>December 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLX2853</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Blood Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

